Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 6/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6560382 | 0.85 | ALDH1A1 (0.50) | KDM4ELMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL7803121 | 0.82 | MAPT (0.43) | MEN1KMT2AMAPTGAA | |
| SCHEMBL7803067 | 0.82 | MAPT (0.51) | HSD17B10MEN1KMT2AMAPTGAA | |
| SCHEMBL7804711 | 0.81 | MAPT (0.43) | KDM4ELMNAKMT2ARAB9AALDH1A1 | |
| SCHEMBL7800966 | 0.80 | NPC1 (0.51) | KDM4ELMNAMEN1KMT2ARAB9A | |
| SCHEMBL7803529 | 0.79 | CCKAR (0.43) | KDM4ELMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL27456552 | 0.74 | ALDH1A1 (0.54) | MEN1KMT2AFAAHRAB9AALDH1A1 | |
| SCHEMBL6560060 | 0.74 | RAB9A (0.47) | KDM4ELMNAMEN1KMT2AFAAH | |
| SCHEMBL8380443 | 0.73 | KDM4E (0.59) | KDM4ELMNAHSD17B10MEN1KMT2A | |
| SCHEMBL8699761 | 0.73 | RAB9A (0.43) | KDM4EKMT2AFAAHRAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1075469-B1 | PIPERAZINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | SAMJIN PHARM CO LTD (KR) | 2004-05-26 | — | — | EP | disclosed |
| US-6683184-B2 | ANTITUMOR AGENTS | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2004-01-27 | — | — | US | disclosed |
| US-20030092910-A1 | Piperazine derivatives and process for the preparation thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2003-05-15 | — | — | US | disclosed |
| EP-1075469-A1 | PIPERAZINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | Samjin Pharmaceutical Co., Ltd. (KR) | 2001-02-14 | — | — | EP | disclosed |
| WO-2000052001-A1 | PIPERAZINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092910-A1 | Piperazine derivatives and process for the preparation thereof | CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS | KDM4E 2023/4885LMNA 3343/4885HSD17B10 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.